Chen, Sunnia T.
Azali, Leylah
Rosen, Lindsay
Zhao, Qiuhong
Wiczer, Tracy
Palettas, Marilly
Gambril, John
Kola-Kehinde, Onaopepo
Ruz, Patrick
Kalathoor, Sujay
Rogers, Kerry
Kittai, Adam
Grever, Michael
Awan, Farrukh
Byrd, John C.
Woyach, Jennifer
Bhat, Seema A.
Addison, Daniel
Funding for this research was provided by:
Leukemia and Lymphoma Society (CDP 2331-20)
National Institutes of Health (R01-CA197870, K23-CA178183, K12-CA133250)
Robert Wood Johnson Foundation (American Heart Association Program Grant)
Article History
Received: 2 February 2022
Accepted: 22 April 2022
First Online: 14 July 2022
Declarations
:
: Not applicable.
: Not applicable.
: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. JCB has received research and has consulted for Acerta Pharma and Pharmacyclics, Inc. FA has received research funding from Innate Pharma and Pharmacyclics and provided consulting services to Gilead Sciences, Pharmacyclics, Inc., Janssen, Abbvie, Sunesis, AstraZeneca, Genentech, and Novartis Oncology, and served on the speakers bureau of Abbvie and AstraZeneca. KR received research funding from Genentech and participated in an advisor board for Acerta Pharma. AK has provided consulting services for Abbvie, Beigene, Bristol Myers Squibb, and Janssen. MG has provided consulting services for Ascerta and Pharmacyclics. JW received research funding from Abbvie, Pharmacyclics, Janssen, Acerta, Loxo, Karyopharm, and Morphosys and has consulted for Janssen and Pharmacyclics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.